The company has introduced several ANDA’s including our most recent approval for Estradiol / Norethindrone Acetate Tablets 1mg/0.5mg (generic version of Activella®), which was received on April 17, 2008. We also received FDA approval to market an ANDA for Oxcarbazepine Tablets on January 11, 2008, and settled our “Paragraph IV” litigation with Novartis concerning Trileptal® on the same date. Our first ANDA approval for Meloxicam Tablets (generic version of Mobic®), was received on July 19, 2006. Breckenridge currently markets Ascomp® w/ Codeine (generic version of Fiorinal® with Codeine), Butalbital, Acetaminophen, Caffeine, & Codeine Phosphate (generic version of Fioricet® with Codeine), Cyclobenzaprine (generic version of Flexeril®), Folic Acid 1mg, Methylprednisolone (generic version of Medrol®), Polyethylene Glycol Powder (generic version of Miralax®), Prednisone 1mg Tablets.